Skip to main content

TCET Pathway Could Accelerate Access to Innovating Technologies

The Centers for Medicare & Medicaid Services (CMS) proposed the Transitional Coverage for Emerging Technologies (TCET) pathway to enable quicker coverage decisions for breakthrough devices needing accelerated regulatory review. As described in JAMA Health Forum, TCET allows tailored oversight based on an innovation’s specific benefits and risks.



TCET focuses on FDA Breakthrough-designated devices for serious conditions supported by limited clinical data for market authorization. By facilitating transitional coverage, TCET aims to help make cutting-edge technologies accessible to patients while additional real-world evidence is gathered to meet CMS’ “reasonable and necessary” standard. 

For developers to optimize TCET’s streamlined approach they should be sure to:

- Pursue FDA Breakthrough designation when criteria are met. This opens the TCET pathway.  

- Engage CMS early on study designs and evidence needs. Incorporate draft guidance on endpoints and real-world data.

- Enable rapid post-market product iterations while maintaining quality.

- Develop safety monitoring and launch protocols satisfying coverage safeguards. 

- Allocate resources for robust data collection and coordination with CMS under shifted evidence requirements.

This proactive, collaborative mindset allows developers to work synergistically with regulators, accelerating patient access while still demonstrating clinical value.

TCET is designed such that it may provide key advantages for AI, machine learning and other novel developments:

- Expedited coverage following truncated registries/pragmatic studies to supplement breakthrough designation data

- Flexibility to refine algorithms and update data inputs without full regulatory restarts

- Clearer expectations and endpoints for pre-market trials to meet CMS evidence needs

- Structured opportunities for manufacturer feedback on study improvements 

- Transitional coverage with “Coverage with Evidence Development” while real-world evidence is gathered

- Streamlined reviews of new data at scheduled milestones to make updated coverage determinations

By embracing TCET’s efficiency, developers can advance high-potential technologies through the pipeline with appropriate oversight. However, challenges may remain even under TCET:

- Non-breakthrough devices still face conventional regulatory burdens

- Reluctance to cover unproven categories like digital health despite clinical promise

- Real-world implementation unknowns and long-term safety monitoring needs 

- Provider training gaps and care integration difficulties

- Ongoing patient access barriers and health disparities

While a major step forward, TCET alone cannot resolve all impediments to emerging technology adoption. Still, TCET represents the type of flexible, sensible regulation needed to balance oversight and progress. As details finalize, TCET could catalyze development of transformative innovations to improve patient outcomes.

As CMS finalizes the pathway details, I’m excited to see TCET in action opening the door to cutting-edge medical breakthroughs. The alacrity of the constantly evolving medtech landscape demands regulatory nimbleness. By embracing agility through initiatives like TCET, CMS is demonstrating an impactful commitment to progress.



Comments

Post a Comment

Popular posts from this blog

Innovative Models for Lowering Drug Spending

Recently, much has been written about the escalating costs of drug prices in the US. Increasing drug prices are present challenges to those who struggle with affordability and access to their medications. The Inflation Reduction Act brought changes to the way the Medicare program reimburses for prescription drugs. Last year, President Biden challenged the Center for Medicare and Medicaid Innovation (CMMI) to develop and test new payment models that can support value-based payments and promote high-quality healthcare. CMMI has recently proposed three models intended to improve affordability and access to drugs as well as measuring the feasibility of implementation.       1. The Medicare High-Value Drug List Model Under this model, Part D plans would be encouraged to offer a low, fixed co-payment across all cost-sharing phases of the Part D drug benefit for a standardized Medicare list of generic drugs that treat chronic conditions. Patients picking plans that participate in the Model wi
Post a Comment
Read more

Bridging the Gap: The Long Road from FDA Approval to Medicare Coverage

A new study published in JAMA Health Forum reveals that the road to Medicare coverage for novel medical technologies is a long and winding one. Researchers found that only 44% of innovative devices and diagnostics approved by the FDA from 2016-2019 had even “nominal” Medicare coverage by 2022. This data highlights major hurdles in the system that delay patient access to beneficial emerging technologies. About the Research The study examined 281 novel products cleared through the FDA from 2016-2019 via the high-risk premarket approval, de novo, and breakthrough 510(k) pathways. These included things like groundbreaking diagnostic tests, implantable devices, and other innovative treatment technologies. The goal was to measure how long it took to establish national or regional Medicare coverage policies for these newly approved products. This is important because Medicare coverage is required before hospitals, physicians and patients can reliably access new technologies. Key Findings The
Post a Comment
Read more

FDA Pilot Program for Certain In Vitro Diagnostic Tests

The U.S. Food and Drug Administration (FDA) has announced a pilot program designed to improve oncology patient care by establishing minimum performance standards for in vitro diagnostic tests (IVDTs) used with a limited number of oncology drug products. An IVDT is a device that provides critical information for the safe and effective use of a therapeutic product. The FDA typically requires a companion diagnostic to receive marketing authorization concurrently with the approval of the corresponding therapeutic product. However, in cases where no satisfactory alternative treatment exists for a serious or life-threatening condition, the FDA may approve a therapeutic product even without a companion IVDT. Currently, laboratory developed tests (LDTs) are being used in such cases, and the FDA exercises enforcement discretion regarding these tests. The pilot program aims to improve drug selection and patient care by establishing minimum performance characteristics for certain LDTs used in id
Post a Comment
Read more